Sodhi et al. conducted a recent study to examine the GI side effects linked to the use of GLP-1 RAs for non-diabetic purposes, particularly focusing on biliary disease, pancreatitis, intestinal obstruction, and gastroparesis. The gene discussed is GLP1R; the disease is intestinal obstruction.